The following entries shall be added at the end of the table in Annex I to Directive 91/414/EEC:
a Further details on identity and specification of active substance are provided in the review report. | ||||||
No | Common name, identification numbers | IUPAC name | Puritya | Entry into force | Expiration of inclusion | Specific provisions |
---|---|---|---|---|---|---|
‘146 | Procymidone CAS No 32809-16-8 CIPAC No 383 | N-(3,5-dichlorophenyl)-1,2-dimethylcyclopropane-1,2-dicarboximide | 985 g/kg | 1 January 2007 | 30 June 2008 | PART AOnly uses as fungicide on the following crops may be authorised:
at rates not exceeding
The following uses must not be authorised:
Member States shall ensure that all appropriate risk mitigation measures are applied. Particular attention must be paid to the protection of:
PART BFor the implementation of the uniform principles of Annex VI, the conclusions of the review report on procymidone, and in particular Appendices I and II thereof, shall be taken into account. Member States must ensure that the authorisation holders report at the latest on 31 December of each year on incidences of operator health problems. Member States may require that elements, such as sales data and a survey of use patterns, are provided so that a realistic picture of the use conditions and the possible toxicological impact of procymidone can be obtained. Member States shall request the submission of further confirmatory data and information to prove the acceptability of the active substance when applied in situations where there is a likelihood of long term exposure of wild mammals, and on the sewage treatment applied in the case of greenhouse applications. Member States shall request the submission of further studies to address the potential endocrine disrupting properties of procymidone within two years after the adoption of the Test Guidelines on endocrine disruption by the Organisation for Economic Cooperation and Development (OECD). They shall ensure that the notifier at whose request procymidone has been included in this Annex provide such studies to the Commission within two years of the adoption of the above test guidelines.’ |